Otorhinolaryngology
A topic in the Science corpus, drawn from 478 papers.
Trusted voices in Otorhinolaryngology
Ordered by the trust Otorhinolaryngology's own network concentrates on each researcher, most first.
- Søren Bentzen — trusted by 4 researchers here
- Kunio Doi — trusted by 3 researchers here
- L. Hall-Stoodley — trusted by 2 researchers here
- P. Stoodley — trusted by 2 researchers here
- W. Craig — trusted by 2 researchers here
- N. Brody — trusted by 1 researcher here
- Vera Mann — trusted by 2 researchers here
- K. Gulabivala — trusted by 2 researchers here
- Y. Ng — trusted by 2 researchers here
- M. Gillison — trusted by 2 researchers here
- R. Biggar — trusted by 2 researchers here
- J. Goedert — trusted by 2 researchers here
Most-cited papers in Otorhinolaryngology
Ordered by the recorded citation count from the source corpus; a citation is not an endorsement.
- Epidemiologic classification of human papillomavirus types associated with cervical cancer. (2003, New England Journal of Medicine) — 6,445 citations
- Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer (2010, New England Journal of Medicine) — 5,857 citations
- Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006, New England Journal of Medicine) — 5,083 citations
- Global epidemiology of oral and oropharyngeal cancer. (2009, Oral Oncology) — 3,448 citations
- Platinum-based chemotherapy plus cetuximab in head and neck cancer. (2008, New England Journal of Medicine) — 3,370 citations
- Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. (2000, Journal of the National Cancer Institute) — 3,171 citations
- Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. (2004, New England Journal of Medicine) — 3,023 citations
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. (2009, Radiotherapy and Oncology) — 2,996 citations
- Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. (2004, New England Journal of Medicine) — 2,975 citations
- Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. (2003, New England Journal of Medicine) — 2,970 citations
- European Position Paper on Rhinosinusitis and Nasal Polyps 2020. (2020, Rhinology) — 2,867 citations
- Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. (2008, Journal of the National Cancer Institute) — 2,711 citations
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (2016, New England Journal of Medicine) — 2,648 citations
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3… (2019, The Lancet) — 2,572 citations
- J OURNAL OF C LINICAL O NCOLOGY Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States (2014) — 2,560 citations
- Antimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis (2004, Otolaryngology Head & Neck Surgery) — 2,451 citations
- Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review (2005, Cancer Epidemiology, Biomarkers and Prevention) — 2,314 citations
- Prognosis of Cerebral Vein and Dural Sinus Thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) (2004, Stroke) — 2,306 citations
- Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data (2000, The Lancet) — 2,306 citations
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children (2000, The Pediatric Infectious Disease Journal) — 2,244 citations
- EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. (2012, Rhinology) — 2,203 citations
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. (2015, The Lancet Oncology) — 2,170 citations
- Head and neck squamous cell carcinoma (2020, Nature Reviews Disease Primers) — 2,075 citations
- World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours (2006, Ear, nose, & throat journal) — 2,031 citations
- Worldwide burden of cancer attributable to HPV by site, country and HPV type (2017, International Journal of Cancer) — 2,030 citations
- Capecitabine and oxaliplatin for advanced esophagogastric cancer. (2008, New England Journal of Medicine) — 1,984 citations
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. (2010, The Lancet Oncology) — 1,955 citations
- A controlled trial of a human papillomavirus type 16 vaccine. (2002, New England Journal of Medicine) — 1,817 citations
- HPV-associated Head and Neck Cancer: A Virus-related Cancer Epidemic – A Review of Epidemiology, Biology, Virus Detection and Issues in Management (2010, The Lancet Oncology) — 1,776 citations
- Sarcoidosis (2014, The Lancet) — 1,712 citations
- Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis (2004, Cancer) — 1,703 citations
- An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. (2003, Journal of Clinical Oncology) — 1,689 citations
- Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) (2005, Head and Neck) — 1,688 citations
- Nomenclature and classification of potentially malignant disorders of the oral mucosa. (2007, Journal of Oral Pathology & Medicine) — 1,673 citations
- Head and neck squamous cell carcinoma (2020, Nature Reviews Disease Primers) — 1,651 citations
- Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. (2010, Journal of Infectious Diseases) — 1,633 citations
- Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. (2007, New England Journal of Medicine) — 1,627 citations
- Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. (2006, The Lancet) — 1,626 citations
- Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. (2011, The Lancet Oncology) — 1,613 citations
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial (2011, The Lancet Oncology) — 1,607 citations
- Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. (2007, New England Journal of Medicine) — 1,599 citations
- Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. (2014, The Lancet) — 1,597 citations
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised… (2009, The Lancet) — 1,578 citations
- Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. (2008, Journal of the National Cancer Institute) — 1,568 citations
- Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. (2008, Journal of Clinical Oncology) — 1,562 citations
- Clinical features and prognostic factors in adults with bacterial meningitis. (2004, New England Journal of Medicine) — 1,559 citations
- Newborn hearing screening--a silent revolution. (2006, New England Journal of Medicine) — 1,540 citations
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. (2016, The Lancet Oncology) — 1,531 citations
- Psychometric validity of the 22‐item Sinonasal Outcome Test (2009, Clinical Otolaryngology) — 1,503 citations
- Efficacy of a pneumococcal conjugate vaccine against acute otitis media. (2001, New England Journal of Medicine) — 1,479 citations
Most active researchers
By papers in this topic: a volume measure, not trust.
- A. Forastiere — 14 papers
- M. Gillison — 13 papers
- J. Bourhis — 11 papers
- X. Castellsagué — 9 papers
- Jean-Pierre Pignon — 8 papers
- Anil K. Chaturvedi — 7 papers
- Silvia Franceschi — 7 papers
- R. Ferris — 7 papers
- Quynh-Thu Le — 6 papers
- S. de Sanjosé — 6 papers
- J. Cooper — 6 papers
- Ruud H. Brakenhoff — 5 papers